文献速递MDS 与骨髓增殖性肿瘤贫血与红细胞疾病

低危骨髓增生异常综合征的诊断算法

Diagnostic algorithm for lower-risk myelodysplastic syndromes.
PubMed 文献 · Leukemia · 2018-06-26

该综述围绕疑似低危骨髓增生异常综合征(包括低增生性MDS)提出最新的诊断路径,强调需采用整合诊断方法,并结合2016年WHO分类的局限性。作者还就大规模平行测序突变筛查的适用患者、时机及数据解读给出建议,尤其考虑到年龄相关克隆性造血的新发现。

要点

  • 疑似低危MDS(含低增生性MDS)应采用整合诊断方法。
  • 2016年WHO分类虽全面及时,但日常临床实践仍存在某些局限。
  • 作者建议明确哪些患者应接受大规模平行测序、何时进行及如何解读数据。

核心结论

  • 对疑似低危MDS(包括低增生性MDS)患者应采用最新的整合诊断方法。
  • 在快速普及大规模平行测序进行突变筛查的时代,作者建议明确哪些患者应接受此类分析、何时进行筛查以及如何解读数据。

研究设计与样本

  • 综述,检索范围未在原文中报告。

主要发现

  • 过去十年揭示了MDS异质性的基因组和免疫学 landscape,提高了MDS诊断和预后判断的准确性与时机。
  • 2016年WHO分类修订版虽全面及时,但日常临床实践仍存在某些局限。
  • 年龄相关克隆性造血的新发现与突变筛查数据的解读尤为相关。

关键数值与推荐

  • 原文未报告具体诊断标准或数值。

临床怎么用

  • 作者建议对疑似低危MDS(含低增生性MDS)采用整合诊断方法。
  • 作者建议明确哪些患者应接受大规模平行测序突变筛查、何时进行以及如何解读数据。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rapid advances over the past decade have uncovered the heterogeneous genomic and immunologic landscape of myelodysplastic syndromes (MDS). This has led to notable improvements in the accuracy and timing of diagnosis and prognostication of MDS, as well as the identification of possible novel targets for therapeutic intervention. For the practicing clinician, however, this increase in genomic, epigenomic, and immunologic knowledge needs consideration in a "real-world" context to aid diagnostic specificity. Although the 2016 revision to the World Health Organization classification for MDS is comprehensive and timely, certain limitations still exist for day-to-day clinical practice. In this review, we describe an up-to-date diagnostic approach to patients with suspected lower-risk MDS, including hypoplastic MDS, and demonstrate the requirement for an "integrated" diagnostic approach. Moreover, in the era of rapid access to massive parallel sequencing platforms for mutational screening, we suggest which patients should undergo such analyses, when such screening should be performed, and how those data should be interpreted. This is particularly relevant given the recent findings describing age-related clonal hematopoiesis.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Mufti GJ, McLornan DP, van de Loosdrecht AA, et al. Diagnostic algorithm for lower-risk myelodysplastic syndromes. Leukemia. 2018. PMID: 29946191. doi:10.1038/s41375-018-0173-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。